All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub

Brought to you by Scientific Education Support

Scientific Education Support

The GVHD Hub is an independent medical education platform, sponsored by Medac and supported through independent educational grants from Incyte, Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My GvHD Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View GvHD content recommended for you

TCT 2022

Share:

Jul 1, 2022

X post image

24 Aug 2022

Catch up with this!📚
Read our summary article of Anita Koshy’s #Tandem22 congress presentation on abatacept treatment of SR cGvHD. From a phase II study, she reported that treatment with abatacept led to a 58% ORR & a reduction in prednisone dosing #GvHD
https://t.co/O8u62ZN3w0

X post image

15 Aug 2022

🎧 During #Tandem22, the GvHD Hub was pleased to speak to Gérard Socié, @HopSaintLouis. We asked, How would you treat acute GvHD in your clinic? 🩺

Listen to the podcast now 👇

https://t.co/FxsvMKA3DZ

X post image

12 Aug 2022

Have you watched this ❓

🎥 During #Tandem22, the GvHD Hub was pleased to speak to @ckitko, @VUMChealth. We asked, What is the latest update on biomarkers for assessing GvHD? 🧪

https://t.co/ImnxTyFQom

X post image

14 Jul 2022

📚Read our summary article of Anita Koshy’s #Tandem22 congress presentation on abatacept treatment of SR cGvHD. From a phase II study of 39 participants, she reported that treatment with abatacept led to a 58% ORR & a reduction in prednisone dosing #GvHD👇
https://t.co/O8u62ZN3w0

X post image

13 Jun 2022

📚Read our summary article of Anita Koshy’s #Tandem22 congress presentation on abatacept treatment of SR cGvHD. From a phase II study of 39 participants, she reported that treatment with abatacept led to a 58% ORR & a reduction in prednisone dosing #GvHD👇
https://t.co/O8u62ZvsEs

X post image

12 May 2022

🎧 During #Tandem22, the GvHD Hub was pleased to speak to Gérard Socié, @HopSaintLouis. We asked, How would you treat acute GvHD in your clinic? 🩺

Listen to the podcast now 👇

https://t.co/FxsvMKA3DZ

X post image

9 May 2022

🎥 During #Tandem22, the GvHD Hub was pleased to speak to @ckitko, @VUMChealth. We asked, What is the latest update on biomarkers for assessing GvHD? 🧪

https://t.co/ImnxTyFQom

X post image

25 Apr 2022

Congress| #Tandem22| @StephanieLeeMD, @fredhutch discusses the correlation between clinical responses in organs and PRO improvements in organ-specific symptoms for cGVHD. She highlights a strong correlation between organ clinical response and clinically meaningful changes #GVHD

X post image

24 Apr 2022

Congress| #Tandem22| @sghmd, @UMNHOT discusses the results of amphiregulin as a monitoring biomarker during treatment of life-threatening aGVHD. She highlights that treatment offers useful longitudinal monitoring for patients #GVHD

X post image

24 Apr 2022

Congress| #Tandem22| Shuntaro Ikegawa, @DanaFarber discusses the use of IL-2 to induce expression of PD-1 on CD4Tregs and improve clinical symptoms in patients with cGVHD. He highlights that treatment resulted in markedly altered Treg populations #GVHD

X post image

24 Apr 2022

Congress| #Tandem22| Najila El Jurdi, @UMNHOT discusses the relationship of the host fecal microbiome with subsequent cGVHD. She reports a distinctive pattern of baseline microbiome and functional metagenomics modulating alloreactivity #GVHD

X post image

24 Apr 2022

Congress| #Tandem22| Dr Annie Im, @UPMCHillmanCC discusses the benefits of a patient-reported treatment response for cGVHD. She highlights limited correlation with NIH or clinician-reported responses, and is associated with failure-free survival #GVHD

X post image

23 Apr 2022

Congress| #Tandem22| Iskra Pusic, @WUSTLmed discusses the use of Belimumab for prophylaxis of cGVHD, highlighting good tolerability and only 1/8 patients developing cGVHD 7 months after completing treatment, suggesting that a longer therapy duration should be explored #GVHD

X post image

23 Apr 2022

Congress| #Tandem22| Alina Markova, @MSKCancerCenter evaluates the use of topical ruxolitinib cream for cutaneous nonsclerotic and superficially sclerotic cGvHD and highlights the identification of a novel gene signature in patient responders #GVHD

X post image

23 Apr 2022

Congress| #Tandem22| Anita Koshy, @harvardmed report results of the phase II study evaluating the clinical response rate of abatacept in steroid-refractory cGVHD. She highlights abatacept is associated with a 49% ORR and leads to reduction in prednisone dosing over time #GVHD

X post image

23 Apr 2022

Congress| #Tandem22| Najla El Jurdi, @UMNHOT discusses mechanisms underlying skin #GVHD, and effects of microbes to treatment outcomes. She highlights distinctive transcriptional signature human cutaneous aGVHD, and has identified potential targets for prevention or treatment

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

TCT 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Newsletter

Subscribe to get the best content delivered to your inbox